Introduction

Diabetes mellitus is a major health problem with almost 400 million adults with type 2 diabetes mellitus (T2DM) worldwide.\(^1\)\(^-\)\(^3\) A physiological phenomenon of insulin resistance results from circannual weight gain, which confers resistance to hypothermia and infections and is thus protective in overwintering and migrating animals.\(^4\)\(^-\)\(^8\) However, in man, the loss of regulation of body weight by the seasonal needs and artificial lighting leads to a loss of seasonal adjustment in adiposity, transforming what is a circannual phenomenon of insulin resistance in overwintering animals to a circadian pattern in humans.\(^9\)-\(^12\) Fat-loaded adipose tissue provokes insulin resistance and contributes to metabolic syndrome through the dysregulated production of free fatty acids and pro-inflammatory adipokines affecting metabolic tissues (skeletal muscle and liver) and modifying inflammatory responses.\(^12\)-\(^14\) The net result is a hyperglycaemic and pro-inflammatory environment that in turn accelerates vascular pathology, explaining the close association between diabetes and vascular ischaemic events.\(^6\)\(^,\)\(^8\) Cardiovascular disease (CVD) remains the main cause of morbidity and mortality in patients with T2DM, with around three-quarter of patients dying of CVD complications.\(^15\) In addition to increased risk of first vascular events, T2DM subjects have worse outcomes following vascular ischaemia compared to subjects with normal glucose metabolism.\(^16\) One of the key links between T2DM and CVD is insulin resistance, which is associated with clustering of vascular risk factors including deranged glucose metabolism, increased very-low-density lipoprotein triglyceride, decreased high-density lipoprotein cholesterol and hypertension.\(^17\)-\(^26\)

Abstract

Obesity-related euglycaemic insulin resistance clusters with cardiometabolic risk factors, contributing to the development of both type 2 diabetes and cardiovascular disease. An increased thrombotic tendency in diabetes stems from platelet hyperactivity, enhanced activity of prothrombotic coagulation factors and impaired fibrinolysis. Furthermore, a low-grade inflammatory response and increased oxidative stress accelerate the atherosclerotic process and, together with an enhanced thrombotic environment, result in premature and more severe cardiovascular disease. The disruption of circadian cycles in man secondary to chronic obesity and loss of circadian cues is implicated in the increased risk of developing diabetes and cardiovascular disease. Levels of melatonin, the endogenous synchronizer of circadian rhythm, are reduced in individuals with vascular disease and those with deranged glucose metabolism. The anti-inflammatory, antihypertensive, antioxidative and antithrombotic activities of melatonin make it a potential therapeutic agent to reduce the risk of vascular occlusive disease in diabetes. The mechanisms behind melatonin-associated reduction in procoagulant response are not fully known. Current evidence suggests that melatonin inhibits platelet aggregation and might affect the coagulation cascade, altering fibrin clot structure and/or resistance to fibrinolysis. Large-scale clinical trials are warranted to investigate the effects of modulating the circadian clock on insulin resistance, glycaemia and cardiovascular outcome.

Keywords

Diabetes, freestyle libre, mean average relative difference, interstitial fluid glucose, hypoglycaemia
While insulin resistance has been attributed to lifestyle changes and the increase in obesity worldwide, understanding the mechanistic pathways underpinning insulin resistance will help to develop more effective management strategies. In particular, the production of the endogenous synchronizer of circadian rhythms, melatonin, is reduced in several cardiovascular diseases and in insulin-resistant subjects.\(^{27-35}\) The anti-inflammatory, antihypertensive, antioxidative activity of melatonin is suggested to favourably influence the development of atherothrombotic disease in diabetes.\(^{36-38}\) This review will use a foundation of circadian cardiometabolic physiology to summarize mechanisms for increased atherothrombotic events and evaluate the potential therapeutic opportunities for melatonin as an anti-atherothrombotic agent, particularly in the context of obesity-related insulin resistance.

A search of PubMed (MEDLINE) was performed starting from the year 1980 until the present, using the following terms either singly or in combination: ‘insulin resistance’, ‘type 2 diabetes’, ‘prediabetic state’, ‘cardiovascular disease’, ‘atherosclerosis’, ‘atherosclerotic plaque’, ‘inflammation’, ‘platelet aggregation’, ‘endothelial dysfunction’, ‘circadian rhythm’, ‘circadian misalignment’, ‘melatonin’, ‘thrombosis’, ‘coagulation’, ‘atherothrombosis’, ‘fibrinogen’, ‘plasminogen activator inhibitor - 1’. Research papers were considered on the basis of their relevance to diabetic atherothrombosis and potential atheroprotective effect of melatonin. Articles that covered circadian rhythm and diabetes, dysglycaemia or cardiovascular disease were selected for inclusion in this review.

**Mechanisms for increased atherothrombotic events in T2DM**

Insulin resistance is associated with endothelial dysfunction, a pro-inflammatory and a prothrombotic environment, which are all key to the development of atherothrombotic disease in T2DM\(^ {39-44}\).

**Endothelial dysfunction and vascular inflammation**

Insulin resistance is associated with a cluster of risk factors that result in endothelial dysfunction, a key abnormality that contributes to the atherothrombotic process (reviewed in Sena et al.\(^ {71}\)). Briefly, endothelial dysfunction causes endothelial cells to express adhesion molecules, thus attracting inflammatory cells, and also increases inter-cellular permeability resulting in accumulation of lipoproteins and inflammatory cells within the vessel wall. Lipid particles migrating to vessel wall are oxidized into highly atherogenic molecules that are taken up by inflammatory cells to form foam cells. An accumulation of foam cells forms the fatty streak, the earliest abnormality in the atherosclerotic process. This is followed by deposition of collagen, gradually resulting in the development of the mature atherosclerotic plaque. Enhanced production of cytokines and growth factors by these inflammatory cells leads to smooth muscle migration and proliferation in the intima, which further contributes to the inflammatory process.\(^ {12,49,54,55}\)
Increased inflammatory cytokines, including tumour necrosis factor α (TNFα) and interleukin (IL)-6, impairs production of a vasodilatory molecule NO (nitric oxide) and also modulates activation of PI3K/Akt pathways further accelerating atherothrombosis in diabetes.\textsuperscript{72–79} In addition, the activation of the pro-inflammatory nuclear transcription factor nuclear factor-kappa B is permitted by the loss of NO, increasing the expression of adhesion molecules, cytokines and chemokines, creating a vicious cycle.\textsuperscript{50,52} Finally, increased production of advanced glycation end product (AGE) and formation of reactive oxygen species (ROS) diminishes endothelial-derived NO and leads to enhanced synthesis of vasoconstrictor prostanoids and endothelin.\textsuperscript{49,80–82}

**Role of circadian rhythm in T2DM and increased thrombotic environment**

The underlying mechanisms for increased thrombosis risk in diabetes subjects are complex and multifactorial. Both the cellular and protein arms of coagulation in diabetes are affected leading to a prothrombotic environment. Platelet activation is increased in diabetes and a key mechanism appears to be reduced NO production, an important inhibitor of platelet activation, secondary to endothelial dysfunction.\textsuperscript{56,83–96} Furthermore, under conditions of hyperglycaemia and insulin resistance, chronic low-grade systemic inflammation drives the haemostatic system towards a prothrombotic state.\textsuperscript{39,40–44} Plasma levels of a number of procoagulant factors are elevated in diabetes patients, including tissue factor, factor VII, von Willebrand Factor, factor VIII and fibrinogen, increasing thrombotic tendency.\textsuperscript{45,49,59–65,80} In addition, diabetes is associated with reduced concentration of antithrombotic factors, such as antithrombin III and protein C,\textsuperscript{83} further adding the prothrombotic milieu. Moreover, the fibrinolytic system is directly affected in diabetes secondary to elevated levels of plasminogen activator inhibitor (PAI)-1 and impaired plasminogen to plasmin conversion, together with reduced enzyme activity.\textsuperscript{16} Interestingly, the EuroClot study involving healthy subjects reported an association between clustering of cardiometabolic risk factors and suppression of fibrinolytic activity, making modulation of hypofibrinolysis in diabetes a possible target to reduce atherothrombotic disease.\textsuperscript{93} Hypofibrinolysis has been recently reported to be an independent predictor of cardiovascular mortality in individuals with acute coronary syndrome treated with modern antithrombotic therapies.\textsuperscript{98} In summary, inflammation-mediated endothelial dysfunction, platelet hyperactivity, increased activation of pro-coagulation factors and impaired fibrinolysis represent a wide spectrum of biological targets with most of them exhibiting circadian variation, thus implicating loss of circadian rhythmicity in the increased thrombotic tendency in diabetes.\textsuperscript{99–103}

The constant exposure to food and the loss of the dark/night stimulus translate into loss of environmental control of circadian rhythmicity, which is implicated in the above-mentioned processes and thus increased risk of developing both diabetes and cardiovascular disease.\textsuperscript{104–106} The master circadian pacemaker in the suprachiasmatic nucleus generates diurnal circadian rhythms secondary to cyclical expression of clock-controlled genes in response to light and food intake.\textsuperscript{107} Clock genes, the Clock and Bmal1, encode transcriptionally activating proteins of the clock system in response to light, whereas Per 1-3 and Cry 1 and 2 genes encode transcriptionally inhibiting proteins of the clock system.\textsuperscript{35} Rudic et al.\textsuperscript{108} reported that an adequate insulin response depends on normal function of the circadian clock. Indeed, Clock mutant Bmal1−/− mice develop a diabetes phenotype with metabolic abnormalities, including impaired gluconeogenesis, hyperglycaemia and hypercholesterolaemia.\textsuperscript{108} Mutations in the Clock gene have also been associated with the metabolic syndrome and vascular dysfunction in man, implicating circadian disruption in the development of both diabetes and associated cardiovascular disease.\textsuperscript{109–111}

In human subjects, data linking circadian misalignment with development of T2DM and adverse cardiovascular events comes either from epidemiological studies in shift workers or from short-term sleep deprivation studies (Table 1). Factors opposing aligned circadian rhythmicity are proposed to underlie higher rates of cardiovascular disease events in shift workers when compared to day workers.\textsuperscript{112–117} Women of the Nurses’ Health Study cohort with 6 years or more of rotating shift work experience were 1.51 [95% confidence interval (CI): 1.12–2.03] more likely to develop coronary heart disease compared to women who had never been shift workers.\textsuperscript{118} A systematic review conducted in 2012 reported that shift work was associated with 41% increased relative risk of coronary events.\textsuperscript{119} Furthermore, circadian misalignment has been shown to have a negative impact on the predictors of cardiovascular disease risk, including pro-inflammatory markers, such as serum IL-6 and C-reactive protein (CRP), and was also associated with hypercoagulability.\textsuperscript{120,121} There is, however, evidence of metabolic and cardiovascular disease markers being improved when shift work schedules are adapted to biological rhythmicity.\textsuperscript{122}

Epidemiological evidence also indicates associations between shift work and development of T2DM.\textsuperscript{27,123} An important prospective clinical study, including 402 night-shift workers and 336 daytime workers followed up for a median of 4 years, identified a five-fold increased risk of developing T2DM/obesity in night-shift workers.\textsuperscript{124} In addition, a prospective study on a cohort of 1529 workers reported a 77% higher incidence of the metabolic syndrome in shift workers.\textsuperscript{125} Misalignment of circadian rhythm and sleep disorders have been associated with the development of metabolic syndrome and prediabetes,
| Study name (reference)                                                                 | Number of individuals recruited | Follow-up period                  | Main conclusions                                                                                                                                                                                                 |
|-------------------------------------------------------------------------------------|---------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Impact of shift work and race/ethnicity on the diurnal rhythm of blood pressure and catecholamines (Yamasaki et al.112) | 99 nurses                       | 24-h period (either day, evening or night shift) | Two independent predictors of higher systolic blood pressure are being African American and working evening or night shifts, which could contribute to adverse effects of shift work.                                                                                   |
| Adverse metabolic and cardiovascular consequences of circadian misalignment (Scheer et al.113) | 10 adults                       | 10-day laboratory protocol       | Circadian misalignment decreases leptin, increases glucose, insulin and blood pressure, and reverses cortisol rhythm.                                                                                      |
| Melatonin rhythms in night shift workers (Sack et al.114)                             | 9 night-shift workers            | 24-h period                      | The sleep times of night-shift workers is not synchronized with melatonin rhythm.                                                                                                                          |
| The circadian melatonin and cortisol secretion pattern in permanent night shift workers (Roden et al.115) | 9 night-shift workers            | 28h                              | Shift work is associated with a rise in melatonin secretion.                                                                                                                                           |
| Prospective study of shift work and risk of coronary heart disease in women (Kawachi et al.118) | 79,109 nurses                   | 4 years                          | Shift work increases the risk of coronary heart diseases in women.                                                                                                                                     |
| Shift work and vascular events: systematic review and meta-analysis (Vyas et al.119)  | 34 studies in 2,011,935 people   | N/A                              | Shift work is associated with an increased risk of atherothrombotic events.                                                                                                                                  |
| C-reactive protein and fibrin clot strength measured by thrombelastography after coronary stenting (Kreutz et al.120) | 54 adults                       | 16–24h                           | Thrombotic risk is associated with raised CRP in patients undergoing coronary stenting and may be linked to procoagulant changes and higher maximal fibrin clot strength independently of fibrinogen concentration. |
| Circadian misalignment increases cardiovascular disease risk factors in humans (Morris et al.121) | 14 adults                       | 8 days                           | Short-term circadian misalignment (12-h inverted behavioural and environmental cycles for 3 days) increases inflammatory markers and blood pressure in healthy adults.                                          |
| Intervention on coronary risk factors by adapting a shift work schedule to biologic rhythmicity (Orth-Gomer122) | 45 adults                       | 4 weeks of clockwise rotation and 4 weeks of counterclockwise rotation | Adapting shift rotation to biological rhythmicity could favourably influence risk factors for ischaemic heart disease, including triglycerides, glucose and blood pressure. |
| Rotating night shift work and risk of type 2 diabetes: two prospective cohort studies in women (Pan et al.123) | 69,269 women in Nurses Health Study I and 107,915 women in Nurses Health Study II | 18–20 years                      | Duration of rotated night-shift work is associated with an increased risk of T2DM.                                                                                                                     |
| Incidence of metabolic syndrome among night-shift healthcare workers (Pietroiusti et al.124) | 738 adults                      | 4 years                          | Night-shift work is associated with the risk of developing metabolic syndrome.                                                                                                                               |
| Rotating shift work and the metabolic syndrome: a prospective study (De Bacquer et al.125) | 1529 adults                     | 6.6 years                        | Rotating shift work increases the risk of developing the metabolic syndrome.                                                                                                                                   |
| Psychological distress and risk of pre-diabetes and type 2 diabetes in a prospective study of Swedish middle-aged men and women (Eriksson et al.126) | 5227 adults                     | 8–10 years                       | Psychological distress, including fatigue and insomnia, increases the risk of developing prediabetes and T2DM in men.                                                                                       |
| Sleep disturbance and onset of type 2 diabetes (Kawakami et al.127)                   | 2649 adults                     | 8 years                          | Sleep disturbance is associated with an increased risk of developing T2DM independently of known risk factors for T2DM.                                                                                      |

CRP: C-reactive protein; T2DM: type 2 diabetes mellitus.
correlated with an elevated risk of T2DM. There is also mounting evidence to demonstrate a close association between sleep deprivation, insomnia, restless leg syndrome and T2DM. Poor sleep quality is associated with increased sympathetic activity, decreased leptin levels and elevated ghrelin levels among other disturbances, leading to a number of metabolic abnormalities, including glucose intolerance.

Moreover, loss of circadian clock synchronization has been suggested as one mechanism for increased thrombotic tendency in diabetes. That view is supported by in vitro studies demonstrating that the Clock/Bmal heterodimers regulate PAI-1 gene expression. The involvement of Clock in the regulation of PAI-1 was also reported in the setting of obesity, supporting the link between obesity, diabetes and CVD through circadian regulation and PAI-1 gene expression.

The above evidence raises the possibility of using circadian rhythm modulators to ‘reset’ normal circadian physiology, in turn reducing metabolic abnormality and vascular risk.

**Melatonin and the circadian rhythm**

The pineal gland is essential as a rhythmic synchronizer, connecting the nervous and the endocrine systems.

The retinohypothalamic-pineal system becomes activated with the onset of darkness, leading to the transmission of neural signals from the suprachiasmatic nucleus (central pacemaker) to the superior cervical ganglia. Noradrenaline release from postganglionic fibres stimulates synthesis of melatonin by pinealocytes. Clock genes encoding transcriptionally activating or inhibiting proteins of the clock system in response to variation in light exposure are the Clock and Bmal1, PERs and CRYs, respectively. Activity of the central pacemaker triggers peripheral circadian oscillators, which are also influenced by local factors, including hormones and glucose. Metabolically active organs including skeletal muscles, liver and adipose tissue display circadian variability in the expression of metabolic transcription factors. Melatonin prevents desynchrony, whereby the peripheral pacemakers are uncoupled from the master clock in the suprachiasmatic nucleus, which may worsen circadian-related metabolic disorders.

**Figure 2.** Melatonin an internal synchronizer of circadian biological rhythmicity. The retinohypothalamic-pineal system becomes activated with the onset of darkness, leading to the transmission of neural signals from the suprachiasmatic nucleus (central pacemaker) to the superior cervical ganglia. Noradrenaline release from postganglionic fibres stimulates synthesis of melatonin by pinealocytes. Clock genes encoding transcriptionally activating or inhibiting proteins of the clock system in response to variation in light exposure are the Clock and Bmal1, PERs and CRYs, respectively. Activity of the central pacemaker triggers peripheral circadian oscillators, which are also influenced by local factors, including hormones and glucose. Metabolically active organs including skeletal muscles, liver and adipose tissue display circadian variability in the expression of metabolic transcription factors. Melatonin prevents desynchrony, whereby the peripheral pacemakers are uncoupled from the master clock in the suprachiasmatic nucleus, which may worsen circadian-related metabolic disorders.
nucleus. Its circadian rhythm-entraining effects are mediated via melatonin receptors MT1 and MT2, which have been implicated in jet lag phenomenon and in the context of sleeping disorders. Animal studies report reductions in visceral adiposity, glucose, insulin and triglycerides following melatonin administration. Although the evidence on the effect of melatonin is limited in human individuals and in the context of insulin resistance, decreased melatonin production found in patients with T2DM, prediabetes and cardiovascular disease suggests a protective role for this hormone in insulin resistance and atherosclerosis.

**Role of melatonin in vascular complications in T2DM**

Evidence gathered in the last 20 years indicates that melatonin influences multiple aspects of cardiometabolic function. Strong evidence comes from studies demonstrating that genetic variants in the melatonin receptor as a result of single nucleotide polymorphisms are related to obesity and are associated with atherosclerosis and the risk of myocardial infarction (MI). Genome-wide association studies indicate a causal relationship between one of the single nucleotide polymorphisms of melatonin receptor MTNR1B and reduced glucose-regulating ability. Furthermore, studies on hypercholesterolemic rats indicated that melatonin leads to lowering of total cholesterol, low-density lipoprotein (LDL) and very-low-density lipoprotein cholesterol levels, suggesting it may protect from atherosclerosis. In addition, animal studies provide evidence on the antioxidant and anti-inflammatory actions of melatonin, which attenuates thermal-induced activation of blood clot formation. These observations together with studies demonstrating low melatonin levels in individuals with coronary artery disease, insulin resistance and T2DM led to the speculation that melatonin has a role in vascular pathology. Therefore, melatonin treatment may prove to be an effective strategy in the management of atherothrombotic disease, particularly in high-risk subjects with deranged circadian rhythm such shift workers. Experimental work provided evidence that melatonin supplementation improves insulin resistance induced by disruption of internal circadian rhythms. In addition to preclinical evidence suggesting exogenous melatonin could also reduce leptin resistance, hyperinsulinaemia and hyperglycaemia in animal models of obesity and metabolic syndrome, melatonin supplementation has also been shown to be associated with significant reduction in HbA1c in a small group of patients with diabetes and insomnia. More recently, studies show that the low levels of melatonin secretion predicts the onset of T2DM in women and that adequate melatonin secretion is thought to reduce the incidence of T2DM.

**Antihypertensive and antioxidant properties of melatonin: potential impact on the atherosclerotic process**

Studies have shown associations between melatonin secretion and reduction in night-time systolic blood pressure. However, did not find a significant relationship between melatonin excretion and diastolic blood pressure, suggesting the relationship is mainly with systolic blood pressure by mechanisms that are not entirely clear.

Oxidative stress plays a central role in the atherosclerotic process, particularly in diabetes. The antioxidant properties of melatonin stem from its detoxifying characteristics, effective scavenging of reactive oxygen and nitrogen species and its ability to enhance antioxidative enzymes. Studies have demonstrated that the rhythm of antioxidant defence is obliterated in pinealectomized rats and by light in humans. In prothrombotic stroke models of ischaemia-induced oxidative damage, in vivo melatonin administered post-ischaemia exhibited a concentration-dependent protection mediated through a reduction in ROS production, associated with decreased infarct size. Similarly, melatonin was shown to have a cardioprotective effect against oxidative injury in the ischaemic/reperfused heart. Decreased serum melatonin and an increase in oxidative stress in patients with MI may indirectly suggest a protective effect of melatonin against cardiovascular disease in man. Finally, subjects with elevated levels of LDL, oxidation of which is implicated in the progression of atherosclerosis, have been reported to have low levels of melatonin. Some studies, but not all, support prevention of LDL oxidation by melatonin, providing another potential mechanism of protection from vascular pathology.

**Melatonin deficiency augments sympathetic activity and influences atherosclerosis and thrombus formation**

Nocturnal secretion of melatonin is reduced in subjects with coronary artery disease, and especially those with acute coronary syndrome (ACS), compared to healthy individuals, and in patients with unstable compared to stable angina. Impaired circadian biological rhythmicity and the lack of the blunting effect of melatonin on sympathetic activity lead to sympathetic activation, contributing to endothelial injury, platelet activation and predisposing vulnerable plaques to rupture. Increased sympathetic activity and activation of the coagulation cascade in the early morning might contribute to the well-described morning peaks in cardiovascular events in patients with coronary artery disease (CAD). In addition, increased sympathetic activity might affect production of a key inhibitor of
fibrinolysis, PAI-1, thus contributing to hypofibrinolysis and increasing the risk of vascular events.175

Urinary 6-sulfatoxymelatonin excretion, a urinary metabolite of melatonin serving as an index of its secretion, is inversely associated with arterial stiffness after adjusting for diabetes and hypertension.176 While this does not prove causality, the association warrants further investigation. Previous work has also shown that melatonin has antithrombotic properties when administered at low doses before or during coronary occlusion, although the exact mechanisms remain to be elucidated.177

**Melatonin affects activated coagulation and platelet aggregation**

A few animal studies have investigated the effect of melatonin on heat-induced inflammatory and coagulation responses. Platelet morphology and elevated levels of fibrinogen, fibrin degradation products, prothrombin activity and CRP following thermal injury were normalized after melatonin administration.156,157 Antithrombotic effects of melatonin were also investigated in randomized-controlled trials in healthy volunteers under acute psychosocial stress conditions. Emotionally triggered catecholamine-induced hypercoagulable state promotes thrombus formation following plaque rupture.178–181 Stress-induced increases in FVII:c and fibrinogen contribute to a hypercoagulable state; however, no statistically significant reductions in these factors were observed after melatonin administration, arguing against a beneficial role for melatonin during thrombotic vascular occlusion.181–183 In healthy young men, the administration of melatonin was associated with a significant reduction in FVIII:c and fibrinogen levels, whereas levels of FVII:c and D-dimer showed no change.173 On the contrary, melatonin could attenuate elevations in D-dimer, suggesting limited thrombus formation and providing support for melatonin potential in reducing atherothrombotic risk.172,183

In addition to the protein arm of coagulation, melatonin is thought to influence circadian variation in platelet activity and several studies have suggested melatonin having direct effects on platelet function. Melatonin has been implicated in the inhibition of platelet aggregation, both spontaneous and induced, mainly through the cyclooxygenase-dependent pathway.184–189 In addition, some studies, but not all, suggest that melatonin elevates the apoptotic events in platelets.190,191 Although both of these effects of melatonin on platelets could potentially limit the process of thrombogenesis, the evidence behind them is not consistent and therefore warrants further exploration.

**Conclusion and future directions**

There is convincing evidence stemming from genetic and epidemiological studies to implicate deranged circadian rhythm in the development of both diabetes and cardiovascular disease. Although the evidence for melatonin as an agent that restores the deranged rhythm is limited in man, indirect evidence suggests a central role for melatonin in abnormal glucose metabolism and/or vascular pathology.

An increased thrombotic tendency in the setting of low-grade chronic inflammation primarily stems from platelet hyperactivity, enhanced activity of prothrombotic coagulation factors and impaired fibrinolysis. Anti-inflammatory and antioxidative properties of melatonin may favourably modulate the prothrombotic and inflammatory environment typically found in atherothrombotic disease.36–38 In particular, the antioxidant activity of melatonin may be atheroprotective in diabetes since hyperglycaemia-induced free radical formation increases oxidative stress, which predisposes to vascular pathology.49,192,193 A cardioprotective and antithrombotic effect of melatonin might also stem from a selective effect on the plasma levels of coagulation measures, including fibrinogen and FVIII:c, both of which are found at increased concentrations in diabetes and are associated with an elevated risk of coronary thrombotic events.54,173 In addition, the atheroprotective potential of melatonin comes from evidence of melatonin deficiency increasing the risk of cardiovascular events by augmenting sympathetic activity, which contributes to platelet activation and hypertension-induced injury to the endothelial cell layer.29

The potential mechanisms of melatonin-mediated atheroprotection are summarized in Table 2. Studies to date suggest that melatonin should be explored as an agent to reduce insulin resistance and prevent diabetes and/or vascular disease, particularly in individuals with deranged circadian rhythm. An advantage of melatonin supplementation is the favourable side effect profile, potentially giving it an advantage over established therapies.145 However, the effects of melatonin to prevent desynchrony are not one-sided and melatonin supplementation could affect endogenous serotonin concentrations and functions of pineal and hypothalamic systems, thus influencing appetitive, emotional and cognitive processes.194 In addition, persistent exposure to melatonin could lead to continuous activation of both melatonin receptors, generating off-target as well as on-target effects. For example, activation of MT1 receptor could generate continuous effects on downstream pathways, such as PLC/DAG/PKC pathway. This in turn could impact neuronal firing and immune system response via a continuous inhibition of leukocyte rolling in the microvasculature.195 In addition, the effects of melatonin metabolites have to be explored and evaluated, in particular, 6-hydroxymelatonin-induced oxidative DNA damage.196 Therefore, more mechanistic studies are needed in different population of patients to not only further understand the role of melatonin in modifying the inflammatory and thrombotic environment that predisposes to vascular disease, but also consider the effect of melatonin and its metabolites on the variety of biological systems.
Key messages

- An increased thrombotic tendency in diabetes stems from platelet hyperactivity, enhanced activity of prothrombotic coagulation factors and impaired fibrinolysis.
- Levels of melatonin, the endogenous synchronizer of circadian rhythm, are reduced in individuals with vascular disease and those with deranged glucose metabolism.
- Anti-inflammatory, antioxidative, antihypertensive and antithrombotic activities of melatonin may favourably modulate the prothrombotic and inflammatory environment typically found in atherothrombotic disease, which make it a potential therapeutic agent to reduce the risk of vascular occlusive disease in diabetes.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship and/or publication of this article.

ORCID iD

Anastasia Otamas https://orcid.org/0000-0002-2796-434X

References

1. Olokoba AB, Obateru OA and Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oman Med J 2012; 27: 269–273.

2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014; 37: S81–S90.

3. WHO. Global report on diabetes 2016, https://apps.who.int/iris/bitstream/handle/10665/204871/9789241565257_eng.pdf;jsessionid=F0E50588BDA1091F000D377575E55AE?sequence=1 (accessed October 2019).

4. Meier AH and Cincotta AH. Circadian rhythms regulate the expression of the thrifty genotype/phenotype. Diabetes Rev 1996; 4: 464–487.

5. Martin SL. Mammalian hibernation: a naturally reversible model for insulin resistance in man. Diab Vasc Dis Res 2008; 5: 76–81.

6. Reaven GM, Scott EM and Grant PJ. Hemostatic abnormalities associated with obesity and the metabolic syndrome. J Thromb Haemost 2005; 3: 1074–1085.

7. Bloomgarden ZT. Insulin resistance concepts. Diabetes Care 2007; 30: 1320–1326.

8. Scott EM and Grant PJ. Neel revisited: the adipocyte, seasonality and type 2 diabetes. Diabetologia 2006; 49: 1462–1466.

9. Sowers JR. Obesity as a cardiovascular risk factor. Am J Med 2003; 115: 37–41.

10. Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001; 286: 1195–1200.

11. Seidell JC. Obesity, insulin resistance and diabetes: a worldwide epidemic. Br J Nutr 2000; 83: S5–S8.

12. Jung UI and Choi MS. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci 2014; 15: 6184–6223.

13. Kim JI, Huh JY, Sohn JH, et al. Lipid-overloaded enlarged adipocytes provoke insulin resistance independent of inflammation. Mol Cell Biol 2015; 35: 1686–1699.

14. Makki K, Froguel P and Wołowczuk I. Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines. ISRN Inflamm 2013; 2013: 139239.
15. Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms. Diabetes Care 2010; 33: 442–449.
16. Kearney K, Tomlinson D, Smith K, et al. Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk. Cardiovasc Diabetol 2017; 16: 34.
17. Stern MP. Diabetes and cardiovascular disease: the ‘common soil’ hypothesis. Diabetes 1995; 44: 369–374.
18. Tabák AG, Herder C, Rathmann W, et al. Prediabetes: a high-risk state for developing diabetes. Lancet 2012; 379: 2279–2290.
19. DeFronzo RA and Abdul-Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol 2011; 108: 3B–24B.
20. Smith U. Impaired (‘diabetic’) insulin signaling and action occur in fat cells long before glucose intolerance: is insulin resistance initiated in the adipose tissue? Int J Obes Relat Met Disord 2002; 26: 897–904.
21. Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409–2415.
22. Bloomgarden ZT. World congress on insulin resistance, diabetes, and cardiovascular disease: part 1. Diabetes Care 2011; 34: e115–e120.
23. Fletcher B and Lamendola C. Insulin resistance syndrome. J Cardiovasc Nurs 2004; 19: 339–345.
24. Haffner SM, Stern MP, Hazuda HP, et al. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990; 263: 2893–2898.
25. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–1607.
26. Alshehri AM. Metabolic syndrome and cardiovascular risk. J Fam Community Med 2010; 17: 73–78.
27. Karlsson B, Knutsson A and Lindahl B. Is there an association between shift work and having a metabolic syndrome? Results from a population based study of 27 485 people. Occup Environ Med 2001; 58: 747–752.
28. Lercher P, Stoschitzky K, Sakotnik A, et al. Melatonin in obesity and insulin resistance. J Pineal Res 2005; 39: 43–49.
29. Yaprak M, Altun A, Vardar A, et al. Decreased nocturnal synthesis of melatonin in patients with coronary artery disease, hypertensive heart disease and dilated cardiomyopathy. Atherosclerosis 2000; 151: P203.
30. Girotti L, Lago M, Ianovsky O, et al. Low urinary 6-sulphatoxymelatonin levels in patients with severe congestive heart failure. Endocrine 2003; 22: 245–248.
31. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez M, et al. Elevated levels of oxidized low-density lipoprotein and impaired nocturnal synthesis of melatonin in patients with myocardial infarction. Atherosclerosis 2005; 180: 101–105.
32. Tutuncu NB, Batur MK, Yildirir A, et al. Melatonin levels decrease in type 2 diabetic patients with cardiac autonomic neuropathy. J Pineal Res 2005; 39: 43–49.
33. Girotti L, Lago M, Ianovsky O, et al. Low urinary 6-sulphatoxymelatonin levels in patients with severe congestive heart failure. Endocrine 2003; 22: 245–248.
54. Tabas I, Williams KJ and Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis update and therapeutic implications. Circulation 2007; 116: 1832–1844.

55. Badimon L, Padro T and Vilahur G. Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease. Eur Heart J Acute Cardiovasc Care 2012; 1: 60–74.

56. Margetic S. Inflammation and hemostasis. Biochimica Medica 2012; 22: 49–62.

57. Carter AM. Inflammation, thrombosis and acute coronary syndromes. Diab Vasc Dis Res 2005; 2: 113–121.

58. Sprague AH and Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 2009; 78: 539–552.

59. Zumbach M, Hofmann M, Borcea V, et al. Tissue factor gene polymorphisms, factor VII C levels and features of insulin resistance in non-insulin-dependent diabetes mellitus. Thromb Haemost 1996; 75: 401–406.

60. Heywood DM, Mansfield MW and Grant PJ. Factor VII gene polymorphisms, factor VII C levels and features of insulin resistance in non-insulin-dependent diabetes mellitus. Thromb Haemost 1996; 75: 401–406.

61. Frankel DS, Meigs JB, Massaro JM, et al. Von Willebrand antigen is elevated in patients with microvascular complications of diabetes mellitus. Diabetes 2008; 118: 2533–2539.

62. Babic N, Dervisevic A, Huskic J, et al. Coagulation factor VIII activity in diabetic patients. Med Glas 2011; 8: 134–139.

63. Soares AL, Sousa MD, Fernandes AP, et al. Hemostatic changes in patients with type 2 diabetes mellitus. Revista Brasileira de Hematologia e Hemoterapia 2010; 32: 482–488.

64. Kloczko J, Wójtukiewicz M, Bielawiec M, et al. Plasma factor XIII and some other haemostasis parameters in patients with diabetic angiopathy. Acta Haematol 1986; 76: 81–85.

65. Bembde AS. A study of plasma fibrinogen level in type-2 diabetes mellitus and its relation to glycemic control. Indian J Hematol Blood Transfus 2012; 28: 105–108.

66. Yarmolinsky J, Bordin Barbieri N, Weinmann T, et al. Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies. Sci Rep 2016; 6: 17714.

67. Dunn EJ, Ariens RA and Grant PJ. The influence of type 2 diabetes on fibrin structure and function. Diabetologia 2005; 48: 1198–1206.

68. Dunn EJ, Philippou H, Ariens RA, et al. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 2006; 49: 1071–1080.

69. Howes JM, Richardson VR, Smith KA, et al. Complement C3 is a novel plasma clot component with anti-fibrinolytic properties. Diab Vasc Dis Res 2012; 9: 216–225.

70. Hess K, Alzahrani SH, Mathai M, et al. A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3. Diabetologia 2012; 55: 1103–1113.

71. Sena CM, Pereira AM and Seica R. Endothelial dysfunction: a major mediator of diabetic vascular disease. Biochim Biophys Acta 2013; 1832: 2216–2231.

72. Laine H, Yki-Järvinen H, Kirvela O, et al. Insulin resistance of glucose uptake in skeletal muscle cannot be ameliorated by enhancing endothelium-dependent blood flow in obesity. J Clin Invest 1998; 101: 1156–1162.

73. Steinberg H, Chaker H, Leaming R, et al. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 2601–2610.

74. Perticone F, Ceravolo R, Candigliota M, et al. Obesity and body fat distribution induce endothelial dysfunction by oxidative stress. Diabetes 2001; 50: 159–165.

75. Wilcox G. Insulin and insulin resistance. Clin Biochem Rev 2005; 26: 19–39.

76. Engin AB and Engin A. Endothelium: molecular aspects of metabolic disorders. Cleveland, OH: CRC Press, 2013.

77. Boucher J, Kleinriders A and Kahn CR. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol 2014; 6: a009191.

78. Munyiparra R and Sowers JR. Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord 2013; 14: 5–12.

79. Munyiparra R, Iantorno M and Quon MJ. An integrated view of insulin resistance and endothelial dysfunction. Endocrinol Metab Clin North Am 2008; 37: 685–711, ix–x.

80. Moreno PR and Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 2004; 44: 2293–2300.

81. Yamagishi SI and Matsui T. Advanced glycation end products and diabetic complications. J Cardiovasc Pharmacol Ther 2003; 8: 253–260.

82. Singh VP, Bari A, Singh N, et al. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol 2014; 18: 1–14.

83. Schneider DJ and Sobel BE. Diabetes and thrombosis. In: Johnstone MT and Veves A (eds) Diabetes and cardiovascular disease. Totowa, NJ: Humana Press, 2001, pp. 107–128.

84. Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med 2007; 262: 157–172.

85. Watson KE, Peters Harmel AL and Matson G. Atherosclerosis in type 2 diabetes mellitus: the role of insulin resistance. J Cardiovasc Pharmacol Ther 2003; 8: 253–260.

86. Lowe GD, Drummond MM, Third JL, et al. Increased plasma fibrinogen and platelet-aggregates in type II hyperlipoproteinaemia. Thromb Haemost 1980; 42: 1503–1507.

87. Zahavi J, Betteridge J, Jones N, et al. Enhanced in vivo platelet release reaction and malondialdehyde formation in patients with hyperlipidaemia. Am J Med 1981; 70: 59–64.

88. Avogaro A, Albiero M, Menegazzo L, et al. Endothelial dysfunction in diabetes mellitus and its role in the mechanisms involved in the repair of platelet aggregates. Diabetes Care 2011; 34: S285–S290.

89. Randriamboavonjy V and Fleming I. Insulin, insulin resistance, and platelet signaling in diabetes. Diabetes Care 2009; 32: 528–530.

90. Westerbacka J, Yki-Järvinen H, Turpeinen A, et al. Inhibition of platelet-collagen interaction. An in vivo
action of insulin is abolished by insulin resistance in obesity. Arterioscler Thromb Vasc Biol 2002; 22: 167–172.

91. Trovati M and Anfossi G. Influence of insulin and insulin resistance on platelet and vascular smooth muscle cell function. J Diabetes Complications 2002; 16: 35–40.

92. Betteridge D, El Tahir K, Reckless J, et al. Platelets from diabetic subjects show diminished sensitivity to prostacycline. Eur J Clin Invest 1982; 12: 395–398.

93. Akai T, Naka K, Okuda K, et al. Decreased sensitivity of platelets to prostacyclin in patients with diabetes mellitus. Horm Metab Res 1983; 15: 523–526.

94. Carrizzo A, Izzo C, Oliveti M, et al. The main determinants of diabetes mellitus vascular complications: endothelial dysfunction and platelet hyperaggregation. Int J Mol Sci 2018; 19: 2968.

95. Cola C, Brugaletta S, Martin Yuste V, et al. Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization. Vasc Health Risk Manag 2009; 5: 101–119.

96. Angiolillo DJ, Suryadevara S, Capranzano P, et al. Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists. Catheter Cardiovasc Interv 2009; 73: 1–14.

97. Carter AM, Cymbalista CM, Spector TD, et al. Heritability of clot formation, morphology, and lysis: the EuroCLOT study. Arterioscler Thromb Vasc Biol 2007; 27: 2783–2789.

98. Sumaya W, Wallentin L, James SK, et al. Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. Eur Heart J 2018; 39: 1078–1085.

99. Paschos GK and FitzGerald GA. Circadian clocks and vascular function. Circ Res 2010; 106: 833–841.

100. Pinotti M, Bertolucci C, Portaluppi F, et al. Daily and circadian rhythms of tissue factor pathway inhibitor and factor VII activity. Arterioscler Thromb Vasc Biol 2005; 25: 646–649.

101. Kanabrocki EL, George M, Hermida RC, et al. Day-night variations in blood levels of nitric oxide, T-TFPI, and E-selectin. Clin Appl Thromb Hemost 2001; 7: 339–345.

102. Soulban G and Labrecque G. Circadian rhythms of blood clotting time and coagulation factors II, VII, IX and X in rats. Life Sci 1983; 45: 407–415.

103. Bremner WF, Sothern RB, Kanabrocki EL, et al. Relation between circadian patterns in levels of circulating lipoprotein(a), fibrinogen, platelets, and related lipid variables in men. Am Heart J 2000; 139: 164–173.

104. Gerhart-Hines Z and Lazar MA. Circadian metabolism in the light of evolution. Endocr Rev 2015; 36: 289–304.

105. Kramer A and Merrow M (eds). Circadian clocks. Berlin: Heidelberg: Springer, 2013.

106. Olds W. Sleep, circadian rhythms, and metabolism: the rhythm of life. Toronto, ON, Canada: Apple Academic Press, 2014.

107. Morris CJ, Yang JN and Scheer FA. The impact of the circadian timing system on cardiovascular and metabolic function. Prog Brain Res 2012; 199: 337–358.

108. Rudic RD, McNamara P, Curtis AM, et al. BMAL1 and CLOCK, two essential components of the circadian clock, are involved in glucose homeostasis. Plos Biol 2004; 2: e377.

109. Viswambharan H, Carvas JM, Antic V, et al. Mutation of the circadian clock gene Per2 alters vascular endothelial function. Circulation 2007; 115: 2188–2195.

110. Anea CB, Cheng B, Sharma S, et al. Increased superoxide and endothelial NO synthase uncoupling in blood vessels of Bmal1-knockout mice. Circ Res 2012; 111: 1157–1165.

111. Scott EM, Carter AM and Grant PJ. Association between polymorphisms in the Clock gene, obesity and the metabolic syndrome in man. Int J Obes 2008; 32: 658–662.

112. Yamasaki F, Schwartz JE, Gerber LM, et al. Impact of shift work and race/ethnicity on the diurnal rhythm of blood pressure and catecholamines. Hypertension 1998; 32: 417–423.

113. Scheer FA, Hilton MF, Mantzoros CS, et al. Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci USA 2009; 106: 4453–4458.

114. Sacz RL, Blood ML and Lewy AJ. Melatonin rhythms in night shift workers. Sleep 1992; 15: 434–441.

115. Roden M, Koller M, Prich K, et al. The circadian melatonin and cortisol secretion pattern in permanent night shift workers. Am J Physiol 1993; 265: R261–R267.

116. Buijs RM, Scheer FA, Kreier F, et al. Organization of circadian functions: interaction with the body. Prog Brain Res 2006; 153: 341–360.

117. Kohsaka A and Bass J. A sense of time: how molecular clocks organize metabolism. Trends Endocrinol Metab 2007; 18: 4–11.

118. Kawachi I, Colditz GA, Stampfer MJ, et al. Prospective study of shift work and risk of coronary heart disease in women. Circulation 1995; 92: 3178–3182.

119. Vyas MV, Garg AX, Jansaviichus AV, et al. Shift work and vascular events: systematic review and meta-analysis. BMJ 2012; 345: e4800.

120. Kreutz RP, Owens J, Breall JA, et al. C-reactive protein and fibrin clot strength measured by thrombelastography after coronary stenting. Blood Coagul Fibrinolysis 2013; 24: 321–326.

121. Morris CJ, Purvis TE, Hu K, et al. Circadian misalignment increases cardiovascular disease risk factors in humans. Proc Natl Acad Sci USA 2016; 113: E1402–E1411.

122. Orth-Gomer K. Intervention on coronary risk factors by adapting a shift work schedule to biologic rhythmicity. Psychosom Med 1983; 45: 407–415.

123. Pan A, Schernhammer ES, Sun Q, et al. Rotating night shift work and risk of type 2 diabetes: two prospective cohort studies in women. PLoS Med 2011; 8: e1001141.

124. Pietroiusi A, Neri A, Somma G, et al. Incidence of metabolic syndrome among night-shift healthcare workers. Occup Environ Med 2010; 67: 54–57.

125. De Bacquer D, Van Risseghem M, Clays E, et al. Rotating shift work and the metabolic syndrome: a prospective study. Int J Epidemiol 2009; 38: 848–854.

126. Eriksson AK, Ekomb A, Granath F, et al. Psychological distress and risk of pre-diabetes and type 2 diabetes in a prospective study of Swedish middle-aged men and women. Diabet Med 2008; 25: 834–842.

127. Kawakami N, Takatsuka N and Shimizu H. Sleep disturbance and onset of type 2 diabetes. Diabetes Care 2004; 27: 282–283.
treatment: a cross-sectional study of the HEIJO-KYO cohort. *Hypertens Res* 2014; 37: 908–913.

164. Parada E, Buendia I, Leon R, et al. Neuroprotective effect of melatonin against ischemia is partially mediated by alpha-7 nicotinic receptor modulation and HO-1 overexpression. *J Pineal Res* 2014; 56: 204–212.

165. Reiter RJ and Tan DX. Melatonin: a novel protective agent against oxidative injury of the ischemic/reperfused heart. *Cardiovasc Res* 2003; 58: 10–19.

166. Tan DX, Manchester LC, Reiter RJ, et al. Ischemia/reperfusion-induced arrhythmias in the isolated rat heart: prevention by melatonin. *J Pineal Res* 1998; 25: 184–191.

167. Reiter RJ, Tan DX, Saimz RM, et al. Melatonin: reducing the toxicity and increasing the efficacy of drugs. *J Pharm Pharmacol* 2002; 54: 1299–1321.

168. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia MJ, et al. Decreased nocturnal melatonin levels during acute myocardial infarction. *J Pineal Res* 2002; 33: 248–252.

169. Murata K, Yano E and Shinozaki T. Cardiovascular dysfunction due to shift work. *J Occup Environ Med* 1999; 41: 748–753.

170. Abuja PM, Liebmann P, Hayn M, et al. Antioxidant role of melatonin in lipid peroxidation of human LDL. *FEBS Lett* 1997; 413: 289–293.

171. Sakotnik A, Liebmann M, Stoschitzky K, et al. Decreased melatonin synthesis in patients with coronary artery disease. *Eur Heart J* 1999; 20: 1314–1317.

172. Wirtz PH, Ehler U, Emini L, et al. Anticipatory cognitive stress appraisal and the acute procoagulant response in men. *Psychosom Med* 2006; 68: 851–858.

173. Wirtz PH, Spillmann M, Bartschi C, et al. Oral melatonin reduces blood coagulation activity: a placebo-controlled study in healthy young men. *J Pineal Res* 2008; 44: 127–133.

174. Muller JE. Circadian variation and triggering of acute coronary events. *Am Heart J* 1999; 137: S1–S8.

175. Von Kanel R, Nelesen RA, Ziegler MG, et al. Relation of autonomic activity to plasmaminogen activator inhibitor-1 plasma concentration and the role of body mass index. *Blood Coagul Fibrinolysis* 2007; 18: 353–359.

176. Obayashi K, Sack K and Kurumata N. Association between urinary 6-sulfatoxymelatonin excretion and arterial stiffness in the general elderly population: the HEIJO-KYO cohort. *J Clin Endocrinol Metab* 2014; 99: 3233–3239.

177. Tengattini S, Reiter RJ, Tan DX, et al. Cardiovascular diseases: protective effects of melatonin. *J Pineal Res* 2008; 44: 16–25.

178. Bhattacharyya MR and Steptoe A. Emotional triggers of acute coronary syndromes: strength of evidence, biological processes, and clinical implications. *Prog Cardiovasc Dis* 2007; 49: 353–365.

179. Servoss SJ, Januzzi JL and Muller JE. Triggers of acute coronary syndromes. *Prog Cardiovasc Dis* 2002; 44: 369–380.

180. Krantz DS, Kop WJ, Santiago HT, et al. Mental stress as a trigger of myocardial ischemia and infarction. *Cardiol Clin* 1996; 14: 271–287.